Tag - MEIP

Developments

Infinity terminates merger accord with MEI Pharma

Infinity Pharmaceuticals (NASDAQ:INFI) terminated its merger agreement to merge with MEI Pharma (NASDAQ:MEIP). At a special meeting of MEI stockholders on July 23, MEI did not obtain stockholder approval for the merger...

July 24, 2023

Markets

Analysts reduce MEI Pharma PTs; Stifel cuts MEI to hold from buy

Stifel downgraded MEI Pharma (NASDAQ:MEIP) to “hold” from “buy” and reduced its price target to $2 from $6 after the FDA discouraged a regulatory filing based on single-arm Phase 2 TIDAL study data, despite previous...

March 25, 2022

Markets

Brookline starts MEI Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $10. The stock closed at $3.08 on Oct. 9. Analyst Leah Rush Cann writes that MEI Pharma is developing...

October 12, 2020

Developments

MEI Pharma gets FDA fast track designation for follicular lymphoma

MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...

March 31, 2020

Tag - MEIP

Infinity terminates merger accord with MEI Pharma

Analysts reduce MEI Pharma PTs; Stifel cuts MEI to hold from buy

Brookline starts MEI Pharma at buy; PT $10

MEI Pharma gets FDA fast track designation for follicular lymphoma

General

More